Search

Extending their collaboration, Genialis and Debiopharm continue working towards a patient classifier to support WEE1 clinical development BOSTON -- Genialis, the RNA biomarker company, today announced an extension of its [...]

First participants initiated Phase 2 dosing for both CF and OTC deficiency in December 2024 Phase 2 interim data for both mRNA therapeutic programs on track for first half of [...]

* Peer-reviewed study demonstrates the unique properties of the company's peptoid-based mRNA delivery vehicles and robust screening and optimization process * Data showed improved performance and lower immunogenicity versus lipid [...]

* Ethris has received $5 million in funding from The Bill & Melinda Gates Foundation to support preparations for ETH47's Phase 2a study including CMC manufacturing processes * ETH47 is [...]

MONTREAL -- AmorChem II Fund L.P. ('AmorChem') is delighted to announce that its RNA Zipcode delivery program has been acquired by Kodikaz Therapeutic Solutions, Inc. ('Kodikaz'), a New York City [...]

CHICAGO -- Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the AACR 2024 Annual Meeting. The abstract, titled 'Analysis of HER2 [...]

Atomic AI's ATOM-1 large language model (LLM) demonstrates state-of-the-art accuracy for predicting RNA structure and function Technology can be exploited to evaluate and optimize key features critical in developing RNA-based [...]

Adiso to Utilize Noninvasive RNA Technology Developed by Geneoscopy as a Precision Immunology Measure in ADS051 Phase 2 IBD Trial ST. LOUIS, Mo. & CONCORD, Mass. -- Geneoscopy, Inc., a [...]

Engineered ARMMs efficiently deliver CRISPR/Cas9 complexes, base editing complexes and RNA therapeutics Additional presentations demonstrate biodistribution to a range of tissue types and scalable manufacturing processes CAMBRIDGE, Mass. -- Vesigen [...]

- New preclinical data demonstratingtherapeutically relevant reductions (>40%) of mutant huntingtin protein (mutHTT) following allele-specific editing of the HTT gene in murine disease models to be presented at CHDI's 18th [...]

* Phase 1 Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Supportive of Once-Daily Dosing Without Ritonavir * Preclinical Animal Data Indicate the Potential for EDP-235 to Reduce Household Transmission and [...]

SEATTLE -- Today, the Access to Advanced Health Institute (AAHI) announced results from a study of their new RNA vaccine against COVID-19. Preclinical studies published in NPJ Vaccinesdemonstrate the ability [...]

* CHMP recommendation based on favorable data from Omicron-adapted vaccines * The Omicron BA.4/BA.5 bivalent COVID-19 booster vaccine combines 15-ug of mRNA encoding the wild-type spike protein of SARS-CoV-2 in [...]

* CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine * The Omicron BA.1-adapted bivalent COVID-19 vaccine combines 15-og [...]

- ARCUS Genome Editing Achieved Substantial Reductions in both cccDNA and Hepatitis B Surface Antigen (HBsAg), 85% and 77% respectively, in HBV-infected Primary Human Hepatocytes (PHH) - Significant Decrease in [...]

DUBLIN -- The 'RNA Based Therapeutic Market by Disease Type, Application and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030' report has been added to ResearchAndMarkets.com's offering. The global [...]

HDT Bio's technology uses self-replicating RNA and has the potential to deliver a COVID-19 vaccine targeting multiple variants, providing broad protection from disease and reduced transmission from breakthrough infections SEATTLE [...]

Preliminary data from ongoing clinical booster study of ARCT-154 (5 mcg) shows a 50-fold increase in neutralizing antibody geometric mean concentration against SARS-CoV-2 using a validated pseudovirus microneutralization (MNT) assay [...]

SOUTH SAN FRANCISCO, Calif. -- Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that [...]

Company testing three existing COVID-19 vaccine booster candidates against the Omicron variant Company announcing a new variant-specific vaccine candidate against Omicron (mRNA-1273.529) CAMBRIDGE, Mass. -- Moderna, Inc., (Nasdaq: MRNA) a [...]

* Second-generation vaccines that combine different advanced DNA, RNA, Protein, and Adjuvant components are critical to providing accessible, broad, and durable protection against current and future likely SARS-CoV-2 variants * [...]

PASADENA, Calif. -- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) collaborator Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, presented clinical data from REEF-1, a Phase 2b [...]

LEXINGTON, Mass. -- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that two abstracts related to the Company's clinical development programs [...]

- Trial to Evaluate Safety and Tolerability of DCR-AUD in Healthy Volunteers - - Trial Includes Ethanol Interaction Assessments to Evaluate Participants' Response to Alcohol After Receiving DCR-AUD - LEXINGTON, [...]

- Imaging study confirms the biodistribution of TTX-MC138 in models of metastatic cancer, supporting TransCode's TTX platform for delivery of RNA targeted therapy to metastatic solid tumors - -- eIND [...]

MUNICH, Germany -- Ethris GmbH announced today that its lead COVID-19 therapeutic candidate, ETH47, has been awarded 'Most Innovative Product Top 3' in the category of Leap Innovations at the [...]

-- Latest Variants of Concern, AY.1 and AY.2 Controls Now Available for Development of Accurate Diagnostic Tests -- SOUTH SAN FRANCISCO, Calif. -- Twist Bioscience Corporation (Nasdaq: TWST), a company [...]

- InitialData Expected in the First Half of 2022 - WATERTOWN, Mass. -- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for [...]

CAMBRIDGE, Mass. -- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Food and Drug Administration (FDA) has approved an [...]

Variants studied included Alpha, Beta, Gamma, Delta, Epsilon and Iota Majority of participants who received primary series maintain detectable blinding and functional antibodies against variants for 6 months CAMBRIDGE, Mass. [...]

Australia has secured 25 million doses of Moderna's COVID-19 vaccine Delivery to begin in the second half of September CAMBRIDGE, Mass. -- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering [...]

SOUTH SAN FRANCISCO, Calif. -- Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that [...]

Ready-to-use, one-step master mix increases SARS-CoV-2 RT-PCR assay efficiency, sensitivity and specificity with minimal amounts of RNA input material BEVERLY, Mass. -- Quantabio, a leading provider of robust DNA and [...]

Serum samples from eight participants obtained one week after second dose of the primary series in the Phase 1 clinical trial of the Moderna COVID-19 Vaccine Serum neutralization assays performed [...]

WATERTOWN, Mass. -- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported new preclinical data for [...]

SOUTH SAN FRANCISCO, Calif. -- Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that [...]

Submission based on Phase 2/3 study of mRNA-1273 in adolescents ages 12 to less than 18 in the U.S. CAMBRIDGE, Mass. -- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering [...]

WATERTOWN, Mass. -- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the company will have [...]

Phase 3 COVE Study: Updated cases show continued strong efficacy, including greater than 90% against cases of COVID-19 and greater than 95% against severe cases of COVID-19, with approximately 6 [...]

-- Additional 'Assay-Ready' Controls for B.1.1.7 Now Available -- SOUTH SAN FRANCISCO, Calif. -- Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality [...]

Study to enroll 60 participants previously vaccinated with mRNA-1273 in Phase 2, to evaluate booster vaccine candidates against the B.1.351 variant first identified in South Africa CAMBRIDGE, Mass. -- Moderna, [...]

Kit expands Agilent's product portfolio aimed at COVID-19 detection SANTA CLARA, Calif. -- Agilent Technologies Inc. (NYSE: A) today announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic [...]

- Phase 2 Initiation Triggers $25 Million Milestone to Dicerna - LEXINGTON, Mass. -- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the 'Company' or 'Dicerna'), a leading developer of investigational ribonucleic acid [...]

MatMaCorp's COVID-19 2SF RNA test detects a highly conserved gene of SARS-CoV-2 and received FDA emergency use approval (EUA) to be performed on company's Solas 8 portable platform Company is [...]

CAMBRIDGE, Mass. -- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Qatar Ministry of Public Health has issued an emergency [...]

Out of an abundance of caution, Moderna launches clinical program to boost immunity to emerging variants Manuscript posted to preprint server; company to host conference call once manuscript is available [...]

Proceeds used to develop small molecule inhibitor of SARS-CoV-2 and other RNA viruses NAARDEN, The Netherlands & MUNICH -- Forbion, a leading European life sciences venture capital firm, today announces [...]

-- RNA Controls Can Help Avoid False Negative Results -- SOUTH SAN FRANCISCO, Calif. -- Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of [...]

Company received NIH RADx funding to scale COVID-19 testing for rural and agricultural communities LINCOLN, Neb. -- MatMaCorp (Materials and Machines Corporation), a developer of comprehensive molecular diagnostic systems, today [...]

SOUTH SAN FRANCISCO, Calif. -- Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it [...]